Treść książki
Przejdź do opcji czytnikaPrzejdź do nawigacjiPrzejdź do informacjiPrzejdź do stopki
Interestingly,asimultaneousincreaseintheproportionofdeathshasbeenobservedatthePPL.Thistrend
mightindicatethatlate-stageHIVcasesarestillbeingmainlyreferredtothePPL,althoughcurrentlythe
mostcommoncauseofdeatharethenon-HIV-relateddiseasessuchasheartattacksandcancers(Chylak-
Nowosielskaetal.,2013).
Figure1.10.DeathsamongHIV/AIDSpatientsatthePPLin2002-2012
In2013,13millionpeoplelivingwithHIVwerereceivingARVtreatment.Theproportionofuntreated
patientshasclearlydecreased,from90%in2006to63%in2013.Between2010and2013,5.6millionpeople
wereprescribedwiththeARVtherapy.OneoutofthreepatientstreatedwithARVintheworldislocatedin
theRepublicofSouthAfrica,whileoneoutofteninUganda,Nigeria,Mozambique,orTanzania.Approx.7%
ofpatientstreatedintheworldliveinIndia.Itisalsoestimatednowadaysthat3outof4peopletreatedfor
HIVinfectionarefromsub-SaharanAfrica.
AccordingtothelatestguidelinesoftheEuropeanAIDSClinicalSociety,everypatientwithrecognized
HIVinfectionshouldreceiveARVtreatment(EACS,2015).Thepercentageofpeoplereceivingtreatmentin
thefirstyearafterregisteringatthePPLincreasedfrom50%in2010-2011to90%in2013-2014(Shepherdet
al.,2015).
TheabovementionedissueposesanewchallengeforthemedicalcareoftheHIV-infectedpopulation
andrequiresincreasesinfundingnotonlyfortreatment,butalsoformoreglobalmedicalattention.
17
